14.21
price down icon2.27%   -0.33
after-market アフターアワーズ: 14.21
loading
前日終値:
$14.54
開ける:
$14.4
24時間の取引高:
41,591
Relative Volume:
0.43
時価総額:
$2.56B
収益:
$420.26M
当期純損益:
$-41.97M
株価収益率:
-56.84
EPS:
-0.25
ネットキャッシュフロー:
$-65.34M
1週間 パフォーマンス:
-5.27%
1か月 パフォーマンス:
+11.19%
6か月 パフォーマンス:
-20.84%
1年 パフォーマンス:
-31.75%
1日の値動き範囲:
Value
$14.19
$14.70
1週間の範囲:
Value
$14.18
$15.20
52週間の値動き範囲:
Value
$11.51
$21.92

Hutchmed China Limited Adr Stock (HCM) Company Profile

Name
名前
Hutchmed China Limited Adr
Name
セクター
Healthcare (1153)
Name
電話
-
Name
住所
-
Name
職員
1,811
Name
Twitter
@hchimed
Name
次回の収益日
2025-03-19
Name
最新のSEC提出書
Name
HCM's Discussions on Twitter

HCM を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
HCM
Hutchmed China Limited Adr
14.21 2.56B 420.26M -41.97M -65.34M -0.25
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
159.27 70.23B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.74 48.23B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.36 48.22B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.93 18.57B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
301.42 13.29B 2.76B 1.11B 898.10M 22.77

Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-11-24 アップグレード Deutsche Bank Hold → Buy
2022-05-04 ダウングレード Deutsche Bank Buy → Hold
2021-09-22 ダウングレード Goldman Buy → Neutral
2021-08-03 開始されました Jefferies Buy
2020-10-02 開始されました Deutsche Bank Buy
2020-03-13 開始されました Cantor Fitzgerald Overweight
2020-02-20 開始されました Goldman Buy
2019-11-19 開始されました CLSA Buy
2019-10-23 繰り返されました BofA/Merrill Buy
2019-07-05 開始されました Macquarie Outperform
すべてを表示

Hutchmed China Limited Adr (HCM) 最新ニュース

pulisher
May 09, 2025

UPDATEInternational companies to host live webcasts at - GlobeNewswire

May 09, 2025
pulisher
May 09, 2025

International companies to host live webcasts at Deutsche - GlobeNewswire

May 09, 2025
pulisher
May 06, 2025

HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial - Barchart.com

May 06, 2025
pulisher
May 05, 2025

Marshall Wace LLP Acquires New Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - The AM Reporter

May 05, 2025
pulisher
Apr 23, 2025

RCSHutchmed China LtdHUTCHMEDData to be Presented at AACR 2025 - TradingView

Apr 23, 2025
pulisher
Apr 21, 2025

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China - Yahoo Finance

Apr 21, 2025
pulisher
Mar 24, 2025

HUTCHMEDOncology portfolio growth expected to continue - Research Tree

Mar 24, 2025
pulisher
Mar 23, 2025

HUTCHMED (China) Limited (NASDAQ:HCM) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - Defense World

Mar 23, 2025
pulisher
Mar 21, 2025

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma - GlobeNewswire Inc.

Mar 21, 2025
pulisher
Mar 20, 2025

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees - GlobeNewswire

Mar 20, 2025
pulisher
Mar 19, 2025

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 - GlobeNewswire

Mar 19, 2025
pulisher
Mar 18, 2025

Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China - The Manila Times

Mar 18, 2025
pulisher
Mar 18, 2025

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 - GlobeNewswire

Mar 18, 2025
pulisher
Mar 09, 2025

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 8th and 9th, 2023 - AsiaOne

Mar 09, 2025
pulisher
Feb 20, 2025

HUTCHMED (HCM) Upgraded to Buy: Here's Why - Yahoo Finance

Feb 20, 2025
pulisher
Feb 20, 2025

Wall Street Analysts Believe HUTCHMED (HCM) Could Rally 72.83%: Here's is How to Trade - Yahoo Finance

Feb 20, 2025
pulisher
Feb 19, 2025

CN NMPA Guides Pharmas, Research Institutes to Enlarge R&D of Innovative Drugs, High-Quality Generic Drugs - AASTOCKS.com

Feb 19, 2025
pulisher
Feb 17, 2025

ABC Arbitrage SA Buys New Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - MarketBeat

Feb 17, 2025
pulisher
Feb 04, 2025

Sea Limited Sponsored ADR (SE) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance

Feb 04, 2025
pulisher
Jan 28, 2025

Crossmark Global Holdings Inc. Increases Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

Jan 28, 2025
pulisher
Jan 16, 2025

CN Healthcare Fund Breaks even w/ Slim Surplus in 2024 - AASTOCKS.com

Jan 16, 2025
pulisher
Jan 13, 2025

HUTCHMED Announces NMPA Full Approval for - GlobeNewswire

Jan 13, 2025
pulisher
Jan 07, 2025

UBS Trims HUTCHMED (00013.HK)TP to $38.7 w/ Rating Buy - AASTOCKS.com

Jan 07, 2025
pulisher
Jan 05, 2025

Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£120m last week - Yahoo Finance

Jan 05, 2025
pulisher
Jan 05, 2025

HSBC Global Research Prefers BeiGene/ SINO BIOPHARM/ HYGEIA HEALTH Given Higher Visibility in CN Pharma & Medical Device Subsectors - AASTOCKS.com

Jan 05, 2025
pulisher
Jan 02, 2025

Hutchmed announces progress, hits milestone with lung cancer treatment - ShareCast

Jan 02, 2025
pulisher
Jan 02, 2025

Market news - Research the market

Jan 02, 2025
pulisher
Jan 02, 2025

Savolitinib Plus Osimertinib Receives Priority Review in China for Pretreated EGFR+ NSCLC With a MET Amplification - OncLive

Jan 02, 2025
pulisher
Jan 01, 2025

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy - The Manila Times

Jan 01, 2025
pulisher
Jan 01, 2025

HUTCHMED Announces NDA Acceptance in China with Priority - GlobeNewswire

Jan 01, 2025
pulisher
Dec 29, 2024

Jane Street Group LLC Raises Stock Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

Dec 29, 2024
pulisher
Dec 28, 2024

HUTCHMED (China) Limited (NASDAQ:HCM) Shares Purchased by State Street Corp - Defense World

Dec 28, 2024
pulisher
Dec 12, 2024

HCMHUTCHMED (China) Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan

Dec 12, 2024
pulisher
Dec 12, 2024

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy - The Manila Times

Dec 12, 2024
pulisher
Dec 11, 2024

HUTCHMED Announces Breakthrough Therapy Designation in - GlobeNewswire

Dec 11, 2024
pulisher
Dec 03, 2024

Hutchmed endometrial cancer treatment gets conditional approval in China - ShareCast

Dec 03, 2024
pulisher
Nov 30, 2024

Why Alibaba Group Holding Limited (BABA) Is One of the Best ADR Stocks to Invest in? - Yahoo Finance

Nov 30, 2024
pulisher
Nov 09, 2024

M&G Plc Has $5.35 Million Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - MarketBeat

Nov 09, 2024
pulisher
Nov 04, 2024

How Trump and Harris plan to address housing affordability - Yahoo Finance

Nov 04, 2024
pulisher
Oct 16, 2024

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® - GlobeNewswire

Oct 16, 2024
pulisher
Oct 16, 2024

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful - The Bakersfield Californian

Oct 16, 2024
pulisher
Oct 15, 2024

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial - Yahoo Finance

Oct 15, 2024
pulisher
Oct 09, 2024

HUTCHMED (China) Ltd (HCM) (Q2 2024) Earnings Call Highlights: Strong US Sales Propel Growth ... - Yahoo Finance

Oct 09, 2024
pulisher
Sep 26, 2024

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - Yahoo Finance

Sep 26, 2024
pulisher
Sep 24, 2024

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda - Yahoo Finance

Sep 24, 2024
pulisher
Sep 19, 2024

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 - Yahoo Finance

Sep 19, 2024
pulisher
Aug 29, 2024

HUTCHMED Voluntarily Withdraws Supplemental New Drug Application in China for Fruquintinib - AASTOCKS.com

Aug 29, 2024
pulisher
Aug 26, 2024

Dr Mehta on the Sequencing of CAR T-Cell Therapy and Bispecific Antibodies in Lymphoma - OncLive

Aug 26, 2024

Hutchmed China Limited Adr (HCM) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$30.13
price down icon 0.82%
$81.74
price up icon 1.62%
$8.77
price down icon 3.52%
$115.71
price down icon 1.54%
drug_manufacturers_specialty_generic RDY
$13.40
price up icon 1.67%
$301.42
price down icon 2.14%
大文字化:     |  ボリューム (24 時間):